Scientific research shows that a peptide, defensin, can reprogram our body to make skin visibly younger and younger every day. Scientists at DefenAge implemented this authentic revolutionary invention in DefenAge’s formulas that were tested and proven in rigorous clinical studies.
The technology is patent-pending, exclusively available in DefenAge, does not belong to the growth factor category and can be combined with almost any skin care regimen.
RESULTS:
A 3-product skin care regimen globally improves the visual appearance of aging skin without irritation, dryness, or inflammation.
Multi-center placebo-controlled double-blind clinical study shows that DefenAge’s Clinical Power Trio “globally improves the visual appearance of aging skin” and “offers most of the advantages of time-honored retinols as well as newer but widely used growth-factor containing cosmeceuticals, without irritation or inflammation, sun-sensitivity, or concerns about neoplasia of the treated skin.”
Journal of Drugs in Dermatology 2018, 17(4): p. 426-441
Amy Taub MD, Vivian Bucay MD, Gregory Keller MD, Jay Williams PhD, and Darius Mehregan MD
The technology is patent-pending, exclusively available in DefenAge, does not belong to the growth factor category and can be combined with almost any skin care regimen.
RESULTS:
A 3-product skin care regimen globally improves the visual appearance of aging skin without irritation, dryness, or inflammation.
- Reduction in visible pores
- Reduction in visible fine and coarse wrinkles
- Reduction in visible oiliness
- Reduction in visible pigmentation
- Improvement in visible skin evenness
- Improvement in skin hydration
- Improvement in a number of other crucial skin’s qualities
Multi-center placebo-controlled double-blind clinical study shows that DefenAge’s Clinical Power Trio “globally improves the visual appearance of aging skin” and “offers most of the advantages of time-honored retinols as well as newer but widely used growth-factor containing cosmeceuticals, without irritation or inflammation, sun-sensitivity, or concerns about neoplasia of the treated skin.”
Journal of Drugs in Dermatology 2018, 17(4): p. 426-441
Amy Taub MD, Vivian Bucay MD, Gregory Keller MD, Jay Williams PhD, and Darius Mehregan MD
